SCHEMBL3467760

SCHEMBL3467760

CN1CCC(c2cccc(C(=O)O)n2)C1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.44
ALOX15 P16050 1/20 0.44
TSHR P16473 1/20 0.44
ACMSD Q8TDX5 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
CNR2 P34972 5/20 0.44
GNE Q9Y223 1/20 0.43
HTR1A P08908 2/20 0.41
DRD2 P14416 2/20 0.41
DRD4 P21917 2/20 0.41
PARP1 P09874 3/20 0.40
PARP2 Q9UGN5 1/20 0.40
KDM5A P29375 1/20 0.40
KCNH2 Q12809 1/20 0.39
MAP4K4 O95819 1/20 0.38
CHRM4 P08173 1/20 0.38
CHRM5 P08912 1/20 0.38
CHRM1 P11229 1/20 0.38
CHRM3 P20309 1/20 0.38
LMNA P02545 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Water SCHEMBL3474017 0.99 KDM4E (0.43) KDM4EALOX15TSHRACMSDTDP1
SCHEMBL412605 0.91 CNR2 (0.49) KDM4EALOX15TSHRACMSDTDP1
Hydrochloric Acid SCHEMBL4291003 0.90 CNR2 (0.48) KDM4EALOX15TSHRACMSDTDP1
SCHEMBL17478650 0.83 KDM4E (0.44) KDM4EALOX15TSHRACMSDTDP1
SCHEMBL7890643 0.82 HTR1A (0.42) CNR2HTR1ADRD2DRD4PARP1
SCHEMBL17896786 0.81 PARP1 (0.55) CNR2DRD2PARP1PARP2MAP4K4
SCHEMBL15019902 0.80 KDM4E (0.59) KDM4EALOX15TSHRACMSDTDP1
SCHEMBL30903051 0.80 KDM4E (0.59) KDM4EALOX15TSHRACMSDTDP1
SCHEMBL9943901 0.79 CNR2 (0.49) KDM4EALOX15TSHRACMSDTDP1
Lithium SCHEMBL29514614 0.78 KDM4E (0.57) KDM4EALOX15TSHRACMSDTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2265600-A1 PYRIDINYL AMIDES FOR THE TREATMENT OF CNS AND METABOLIC DISORDERS Pfizer Inc. (US) 2010-12-29 EP disclosed
WO-2009098576-A1 PYRIDINYL AMIDES FOR THE TREATMENT OF CNS AND METABOLIC DISORDERS PFIZER INC. (US) 2009-08-13 WO disclosed
WO-2009098576-A1 PYRIDINYL AMIDES FOR THE TREATMENT OF CNS AND METABOLIC DISORDERS PFIZER INC. (US) 2009-08-13 WO disclosed
US-20090197859-A1 Pyridinyl Amides for the Treatment of CNS and Metabolic Disorders PFIZER INC. 2009-08-06 US disclosed
US-20090197859-A1 Pyridinyl Amides for the Treatment of CNS and Metabolic Disorders PFIZER INC. 2009-08-06 US disclosed
US-20090197859-A1 Pyridinyl Amides for the Treatment of CNS and Metabolic Disorders PFIZER INC. 2009-08-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090197859-A1 Pyridinyl Amides for the Treatment of CNS and Metabolic Disorders HTR6, HTR5A, TPH1 KDM4E 2255/4885ALOX15 660/4885TSHR 74/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.